Stocktoria
Cytosorbents Corp CTSO
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2005-06-17
Cytosorbents Corp statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 71.5% | 69.9% | 70.6% | 59.8% | 74.4% |
| Operating margin | -39.8% | -46.2% | -102.8% | -90.9% | -52.7% |
| Net margin | -22.1% | -58.2% | -94.1% | -94.6% | -56.9% |
| FCF margin | -33.8% | -41.3% | -71.4% | -98.9% | -40.9% |
| Return on assets | -18.6% | -43.7% | -55.2% | -51.9% | -27.4% |
| Return on equity | -138.9% | -186.5% | -124.6% | -92.8% | -39.2% |
| Debt / equity | 2.82× | 1.26× | 0.21× | 0.14× | — |
| Current ratio | 2.13 | 2.20 | 1.81 | 3.48 | 4.70 |
| Revenue growth | 4.1% | 14.5% | -10.4% | -19.6% | 5.3% |
Source: SEC EDGAR filings · CIK 0001175151 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.